B+
Bull case
20%
Probability
Target price
$410.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
PRAX
Praxis Precision MedicinesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Praxis still has a large cash runway (~$1.4bn at 3/31/26) and the POWER1 readout was not a total washout: the secondary 50% response endpoint was met, higher-dose separation looked better later in the study, adverse-event discontinuations were <10%, and ~90% of treated patients entered OLE [#SEC-8K-2026-06-01; #SEC-10Q-2026-05-07].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.3.
What can break
Any program modification could push out timelines, complicate trial design, or lower investor confidence in the focal-onset seizure opportunity.
Momentum
60
Value
41
Sentiment
23
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $225.00 · Bull $410.00 · Bear $115.00Analysis 2026-06-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $638.68
Why
Momentum60 · Δ7d -7.3
Value41 · Δ7d -0.0
Sentiment23 · Δ7d +3.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.3.
Contradictions & invalidation
- • Any program modification could push out timelines, complicate trial design, or lower investor confidence in the focal-onset seizure opportunity.
- • POWER1 missed its primary endpoint and POWER2 enrollment is paused, which raises execution risk and may delay or reduce the value of the vormatrigine franchise.
- • The primary endpoint miss on vormatrigine is a real credibility hit for one of the key neuroscience assets; management is pausing POWER2 and will need to justify modifications before investors re-assign value.
Catalyst clock
2026-06-05
Immediate de-risking after POWER1 miss
Lead driver: Sentiment · See AI snapshot
Momentum
60
9% active weight
Current posture
7d trendImproving
Δ7d
-7.3
Δ21d
-29.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
23
62% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
+7.4
Why this grade
Composite grade F. Momentum 59.8 / Value 41.2 / Sentiment 22.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$225.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$10.51B
Beta
2.87
Shares Out
27.92M
P/E (TTM) · Derived
-27.9
P/S (TTM)
927.91
P/FCF (TTM) · Derived
-32.37
Rev YoY
-100.0%
EPS YoY
-13.2%
Gross Margin
+97.9%
Op Margin
-3927.5%
Net Debt
-$599.22M
Current Ratio
15.73
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data